The rising prevalence of cardiovascular and pulmonary disorders such as arrhythmia and heart valve imbalance are the major factors driving the cardiopulmonary stress testing systems market. Furthermore, increasing incidences of lifestyle diseases coupled with heart and lung disorders are the factors propelling the cardiopulmonary stress testing market. The cardiopulmonary test evaluates and detects heart failures, ischemic heart disease, shortness of breath, and pulmonary disorders. As of 2013, cardiovascular diseases are the major cause of deaths globally which is becoming a major concern for WHO as well as various healthcare institutions all over the world and is also a factor expected to drive the cardiopulmonary stress testing devices market during the forecast period.
The cardiopulmonary stress testing system market is segmented on the basis of product and application. On the basis of application, the market is divided into ETT (Exercise Tolerance Test) testing devices, the ECHO (Echocardiograph) testing devices, and the NUC (Nuclear Stress Test) testing devices. The ETT testing device attributes the largest share in the market owing to the accuracy and the least operating time taken by these devices. On the basis of product, the cardiopulmonary stress testing system market is bifurcated into exercise stress testing devices and pharmacological stress testing devices. The ETT devices cover the largest market share owing to its cost-effectiveness and multiple uses of these devices. However, due to the increasing geriatric population with decreased functional capacity, the pharmacological stress testing device is establishing its foothold in the global cardiopulmonary stress testing systems market during the forecast period.
Geographically, the entire cardiopulmonary stress testing systems market is segmented into North America, Europe, Asia Pacific, and RoW. North America represents the largest market share as medical professionals are well aware of the advantages of CPST in this region. Asia Pacific is expected to grow at a high pace due to the high prevalence of patients suffering from cardiovascular and pulmonary diseases in this region. High level of air pollution has resulted in an exponential increase in respiratory and cardiovascular diseases all over the world.
The key players operating in cardiopulmonary stress testing systems market are Thermo Fisher Scientific Ltd., Philips Healthcare, Care Medical Ltd., Cosmed Medical and Cardiac Science Corporation, GE Healthcare, Cardinal Health, Commercially available CPST systems are StressVue Stress Testing system by Philips Healthcare and CASE ES Ergospirometry testing System by GE Healthcare.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.